Clinical Trial Update: A Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy (SIRROUND-T) [Phase 3]

View source ↗

Summary

Phase 3 study evaluating subcutaneous sirukumab (CNTO 136) in active rheumatoid arthritis patients with inadequate response to anti-TNF therapy has completed. R…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Sirukumab (sirukumab)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Arthritis, Rheumatoid | Phase 3 | Status: COMPLETED | Results posted: 2018-02-05